Cancer & SURVIVEiT News
Category Filter:
FDA approves olaparib for adjuvant treatment of high-risk early breast cancer
FDA approves olaparib for adjuvant treatment of high-risk early breast cancer On March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment…
Breast Cancer Patient Stories Plus Stats On Genetic Stats
October is breast cancer awareness month, so we’re shedding light on this particular type of cancer. Aside from skin cancers, breast cancer is the most common type of cancer women…
TNBC Foundation Explains 3 Myths About Triple Negative Breast Cancer
Triple Negative Breast Cancer Awareness is all about bringing attention to this particular type of breast cancer and understanding what makes it different from other types of breast cancer. The…
FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast
FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer On June 29, 2020, the Food and Drug Administration approved a new fixed-dose combination of pertuzumab, trastuzumab, and…
FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast
FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics,…
FDA approves tucatinib for patients with HER2-positive metastatic breast cancer
FDA approves tucatinib for patients with HER2-positive metastatic breast cancer On April 17, 2020, the Food and Drug Administration approved (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine,…
FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast
FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics,…
FDA approves tucatinib for patients with HER2-positive metastatic breast cancer
FDA approves tucatinib for patients with HER2-positive metastatic breast cancer On April 17, 2020, the Food and Drug Administration approved (TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine,…
Breast Cancer News | Some Patients NED After New Combo
Big news for breast cancer patients! The percentage of patients that had a complete response (meaning NO EVIDENCE OF DISEASE!) to Imfinzi + Lynparza + chemo are significantly increasing in…